# Immunogenomics Core

> **NIH NIH P50** · ROSWELL PARK CANCER INSTITUTE CORP · 2021 · $155,649

## Abstract

Abstract
The primary objective of the Immunogenomics Core is to perform comprehensive immunophenotyping,
functional analyses, and genetic and epigenetic monitoring in peripheral blood and the tumor microenvironment
and investigate tumor antigen-specific immune responses for the immunotherapeutic approaches being
developed and tested in Individual Research Projects 1-3 of the Roswell Park Ovarian Cancer SPORE. It will be
also responsible for immunologic and genomic assays for Career Enhancement Program (CEP) and
Developmental Research Program (DRP). In conjunction with the Biospecimen and Pathology Core, morphology
and localization of immune cells on pre- and post-immunotherapy tumor sections will be analyzed by highly
multiplexed Imaging Mass Cytometry (IMC). Additionally, in conjunction with the Biostatistics and Bioinformatics
Core, neoantigens, transcriptome analysis, epigenetic changes and TCR sequencing will be determined for
Individual Research Project 1 and 3. The Core will routinely provide SPORE investigators high quality, state-of-
the-art CyTOF, IMC, Seahorse assays, cell culture, cell isolation, flow cytometry, ELISPOT, ELISA, multiplex
cytokine bead array, RNA-seq, whole exome sequencing, TCR-seq, and Methyl-Seq.
The specific aims of the Immunogenomics Core are to:
1) Design and optimize immunologic and genomic assays for Individual Research Projects, CEP and DRP, and
 provide state-of-the-art immunophenotyping, transcriptome analysis, TCR sequencing, epigenetic changes
 and functional analyses of immune cells in peripheral blood and tumor microenvironment of patients who
 receive advanced immunotherapies in the Ovarian Cancer SPORE.
2) Run whole exome sequencing for tumor and peripheral blood samples to identify mutations and HLA types
 and confirm T-cell reactivity against the predicted neoantigens for DC-peptide vaccine in Individual Research
 Project 3.
In addition to these established immunoassays, the Immunogenomics Core will be developing new
methodologies/markers and making them available to the SPORE investigators. It also has a significant
educational role, working with all SPORE investigators, including PIs, technicians and young investigators on
their assay development, proper use of instrumentation, and interpretation of their data.

## Key facts

- **NIH application ID:** 10171146
- **Project number:** 2P50CA159981-07A1
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** Junko Matsuzaki
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $155,649
- **Award type:** 2
- **Project period:** 2013-09-18 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10171146

## Citation

> US National Institutes of Health, RePORTER application 10171146, Immunogenomics Core (2P50CA159981-07A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10171146. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*